Cycle on Aug 10, 2026

I will begin by listing the active threads and watches for this topic to understand what has been flagged for monitoring in past cycles.

I will start by pulling the market views for the core companies to anchor our quantitative findings in current financial data and check for recent news, earnings releases, and valuation metrics. Let's query Eli Lilly (LLY), Novo Nordisk (NVO), Amgen (AMGN), Viking Therapeutics (VKTX), and Structure Therapeutics (GPCR).

I will now pull the market view for Novo Nordisk (NVO) to see their financial status.

I will now pull the market view for Amgen (AMGN) to see how their Q2 2026 earnings release went (which was scheduled for August 4, 2026). Let's see if the watch was triggered and if there is any update on MariTide.

I will now pull the market view for Viking Therapeutics (VKTX) to see their financial status.

Now I will pull the market view for Structure Therapeutics (GPCR) to see their Q2 earnings release (which was scheduled for August 6, 2026). Let's see if that watch was triggered too.

Excellent. The market views show that: 1. **Amgen (AMGN)** beat EPS estimates and reported Q2 2026 earnings on June 30 (latest q reported in system was June 30, 2026, or did it report on Aug 4?). Wait, let's search for "Amgen Q2 2026 earnings" to get the precise details of their release on August 4, 2026. 2. **Structure Therapeutics (GPCR)** reported Q2 2026 financial results on August 7, 2026 (or August 6/7) and announced the initiation of Phase 3 clinical trials for aleniglipron. Let's research this. 3. **Viking Therapeutics (VKTX)** reported Q2 2026 results recently (around July 29, 2026, as per prior findings, but also has news about universal shelf and ATM stock offerings in early August). Let's search for Viking's ATM and shelf registration. 4. Let's do a search on Amgen's Q2 2026 earnings call, MariTide updates, and other core developments. Let's start by searching for Amgen's Q2 2026 earnings release details, specifically looking for updates on MariTide.

Let's fetch the full Amgen Q2 2026 news release or an article about their earnings call highlights to understand what details were shared about MariTide, particularly the clinical trials, dosing schedules (monthly or quarterly), the MARITIME program, and any pipeline updates. We also want to check if they dropped AMG 513 or any other weight-loss candidate. Let's do a search on `Amgen "Q2 2026" "MariTide" OR "AMG 513"`.

Let's fetch the full text of `https://finance.yahoo.com/healthcare/articles/amgen-q2-2026-earnings-beat-132232577.html` or `https://allsci.com/news/earnings-call-insights/amgen-amg-513-discontinuation-discontinues/` or the official release `https://investors.amgen.com/news-releases/news-release-details/amgen-reports-second-quarter-2026-financial-results` to see exactly what Amgen reported about MariTide and the discontinuation of AMG 513. Let's fetch the official release first since it's the primary source.

This is extremely detailed. In Q2 2026, Amgen reported: - Total revenues of $10.05B (+10% YoY). - Non-GAAP EPS was $6.29, up 4% YoY (beating expectations of $5.60). - GAAP EPS was $4.37, up 65% YoY. - Free cash flow was $3.49B (vs $1.91B in Q2 2025). - Amgen raised full-year 2026 guidance: revenue of $38.2B to $39.4B and non-GAAP EPS of $22.30 to $23.50 (previously it was lower or we can verify). - **MariTide (AMG 133)**: - Long-acting design supports starting with monthly dosing, and staying on MariTide with as few as 4 or 6 doses per year. - Phase 3 programs are highly active: - **MARITIME-1** (obesity/overweight, without T2D) and **MARITIME-2** (with T2D) are ongoing. - **MARITIME-CV** (cardiovascular outcomes), **MARITIME-HF** (heart failure), **MARITIME-OSA-1** and **MARITIME-OSA-2** (obstructive sleep apnea) are enrolling. - **MARITIME-SWITCH** is enrolling adults living with obesity or overweight who will be switching from weekly tirzepatide (Lilly's Zepbound) or weekly semaglutide (Novo's Wegovy) to MariTide on an *every eight-week or quarterly dosing schedule*. This is a huge competitive threat to Lilly and Novo! - **MARITIME-1 EXTENSION** and **MARITIME-2 EXTENSION** are enrolling to evaluate weight loss maintenance with monthly, every eight-week, or quarterly dosing. - Three Phase 3 studies in T2D will be initiated in 2026. - A Phase 2b liver fat reduction study is enrolling. - **AMG 513**: "Future development of AMG 513 will be discontinued." (A Phase 1 study in adults living with obesity will remain ongoing to follow enrolled participants through completion of the study). Let's see what AMG 513 is. It was an early-stage oral weight loss candidate? Let's search to confirm what AMG 513 is. - Let's check if there is any mention of the tax dispute in the Q2 call or recent filings. The watch `Amgen 2010–2015 IRS Tax Court Ruling` is scheduled for H2 2026. The Q2 press release mentions "The increase [in free cash flow] reflects the final repatriation tax payment in the second quarter of 2025..." and "Long-term tax liabilities $2.844B". Let's search for "AMG 513" to see what target/mechanism it had and why it was discontinued, and check the details of Structure Therapeutics' Q2 2026 earnings. Let's do a quick search on AMG 513.

Let's fetch the full text of `https://www.biospace.com/business/amgens-maritide-stands-alone-after-obesity-cull-while-analysts-seek-more-m-a` or `https://allsci.com/news/earnings-call-insights/amgen-amg-513-discontinuation-discontinues/` or search for Amgen earnings call transcripts regarding the discontinuation of AMG 513 and the MariTide extension/switching trials. This is crucial. Let's do a search.

This is excellent! We have a ton of details about Amgen's Q2 earnings, the discontinuation of AMG 513, and the MariTide clinical developments. Let's do a quick search on the other two articles shown in the BioSpace search, which are: 1. `Lilly confident in slow and steady Foundayo launch, as ex-US sales shine` (August 5, 2026) 2. `Lilly, FDA retatrutide biologic dispute comes to a head as submission nears` (August 5, 2026) These are extremely important for Eli Lilly (LLY). Let's search for those exact titles.

This is amazing! Let's fetch the full text of `https://www.biospace.com/business/lilly-confident-in-slow-and-steady-foundayo-launch-as-ex-us-sales-shine` so we can learn more about Foundayo (orforglipron) sales, Novo Nordisk's rival oral GLP-1, and the Eli Lilly Q2 2026 earnings call details. This is an incredible development: Eli Lilly's oral obesity pill Foundayo (orforglipron) was approved on April 1, 2026! Let's fetch this page.

This is incredibly useful! Let's analyze what we have: 1. **Eli Lilly (LLY)**: - Q2 2026 revenue was $23 billion, a "blowout" performance. (In our market view of LLY, it says latest Q reported was 2026-06-30 with rev $22.97B, which is indeed $23 billion!). Let's confirm that. - Lilly raised full-year 2026 revenue guidance to a range of $85 billion to $87 billion (up from $82B-$85B previously). - **Foundayo (orforglipron)**: Lilly's oral obesity drug was FDA-approved on April 1, 2026. - It generated $98 million in sales in Q2 2026, its first quarter available. - In the U.S., uptake is slow but growing. Volume doubled from a month ago, and subscribers grew from 8,000 to 36,000. Nearly 1 in 4 patients are choosing Foundayo for initial starts. - Ex-U.S. sales are showing strong potential: it brought in $31 million in the UAE alone in Q2. - Comparatively, Novo Nordisk's oral obesity pill (the Wegovy pill, which was approved in December 2025) generated $496 million in Q2 2026 (up from $355 million in its initial sales period). - **Retatrutide**: - Lilly's highly anticipated "triple-G" (triple-acting) obesity candidate (Phase 3 trials TRIUMPH-2 and TRIUMPH-3 showed weight loss topping 20% at 80 weeks). - Lilly plans to file for regulatory approval of retatrutide in the **first quarter of 2027** (previously expected later in 2026). They are collecting some manufacturing-related data prior to submission. - A major legal battle between Lilly and the FDA has come to a head: Lilly filed a lawsuit in September 2024 claiming retatrutide should be classified as a **biologic** (and filed under a Biologics License Application or BLA), which would give it 12 years of market exclusivity. The FDA classifies it as a **drug** (subject to a New Drug Application or NDA, which only has 5 years of exclusivity) because the FDA argues it does not meet the definition of a protein with 40 or more alpha amino acids. Retatrutide has 41 amino acids, but the FDA argues it does not have 40 or more *alpha* amino acids. - The courts vacated the FDA's biologic designation decision but returned the question of whether it is "analogous to a protein" to the FDA. Lilly has appealed and is pursuing a BLA, hoping to resolve the issue before its Q1 2027 submission. - We should update our watches and findings to reflect this! Let's check the watch list. We have a watch: `Eli Lilly Foundayo (Orforglipron) Europe and UK Commercial Launch` with fire date 2027-03-31. Let's see if there is any other watch or thread. Wait, let's look at Structure Therapeutics (GPCR). They reported Q2 2026 results on August 7, 2026. Let's search for "Structure Therapeutics" Q2 2026 earnings to get the specific details of their Phase 3 aleniglipron (GSBR-1290) trial initiation, cash, and the Kailera '183 European patent challenge. Let's do a search.

Let's fetch the SEC filing of Structure Therapeutics from August 6, 2026: `https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/tm2622407d1_ex99-1.htm`. This is the official press release for their Q2 2026 earnings, which contains exact information about aleniglipron's Phase 3 ACCOMPLISH program, cash balance, and other updates. Let's fetch it!

Ah, the fetch failed due to a timeout. Let's try searching for the press release text or another source. Let's do a search for the text of that press release: `Structure Therapeutics "Q2 2026" "ACCOMPLISH" OR "cash" OR "August 6, 2026"`.

This is beautiful! Let's examine the details for **Structure Therapeutics (GPCR)**: - Dosed first patients in the Phase 3 **ACCOMPLISH** program (ACCOMPLISH-1 and ACCOMPLISH-2), which is their registrational Phase 3 program for oral aleniglipron (GSBR-1290) in chronic weight management. Dosing first patients was announced on August 6, 2026. This fires the watch `Structure Therapeutics Q3 2026 Phase 3 Aleniglipron Trial Initiation` (GPCR)! Let's record the event. - Cash, cash equivalents, and short-term investments were **$1.3 billion** (or $1.34B according to some sources, let's verify if it's $1.3 billion or $1.34 billion exactly. The press release says "Cash, cash equivalents and short-term investments of $1.3 billion as of June 30, 2026", while our market view says cash was $272.6 million. Wait! The market view only shows cash of $272.6M, but the company's total liquidity including short-term investments is $1.3 billion. They expect this to fund projected operations and key clinical milestones through the end of 2028). - Q2 2026 Net Loss was **$106.2 million** (our market view says net income was $-106.2M, which is a net loss of $106.2M. This is perfectly aligned!). - Upcoming aleniglipron data in H2 2026 (specifically Q4 2026): - **Body Composition** clinical trial assessing fat loss over 44 weeks (data expected in Q4 2026). - **SWITCH** clinical trial assessing the transition from an approved injectable GLP-1 to once-daily oral aleniglipron for long-term weight loss maintenance (data expected in Q4 2026). - Preclinical combination data of aleniglipron and ACCG-2671 (oral amylin receptor agonist) was presented at ADA in June 2026, demonstrating additional weight loss compared to monotherapy. A combination clinical trial is expected to initiate in Q4 2026. - Let's check if there is any update on the Kailera '183 European patent challenge. Let's do a search on `Structure Therapeutics "patent" OR "Kailera" OR "1782" OR "court"` to see if there are any recent court filings or updates. Let's do that.

Let's fetch `https://dockets.justia.com/docket/california/candce/3:2026mc80216/474787` or search for updates on `3:2026mc80216` (Kailera Therapeutics v. Structure Therapeutics) to see if there have been any rulings or filings after July 22, 2026. Let's do a search.

Let's check if there are any other filings in that Pacermonitor or Justia docket. It seems the application was filed on July 22, 2026, and is an active case with no final ruling yet. The watch `Kailera v. Structure Section 1782 Discovery Ruling` has a fire date of 2026-12-31, so it is still active and has not fired yet. Wait, let's look at the other active watches we have: 1. `Structure Therapeutics Q2 2026 Earnings Release` (fire date 2026-08-06). This has fired! 2. `Amgen Q2 2026 Earnings Release` (fire date 2026-08-04). This has fired! 3. `Structure Therapeutics Q3 2026 Phase 3 Aleniglipron Trial Initiation` (fire date 2026-09-30). This has fired! In their Q2 release on August 6, 2026, they announced that the first patients have been dosed in the Phase 3 ACCOMPLISH program. This is a huge milestone. Let's do a search on Novo Nordisk's latest earnings and updates. Novo Nordisk reported earnings recently as well (around August 6, 2026, or earlier in the week). Let's search for "Novo Nordisk" Q2 2026 earnings to see what they reported regarding Wegovy sales, Wegovy oral pill (approved in Dec 2025), and any other competitive dynamics or manufacturing updates. Let's do a search.

The search budget is spent! This is perfect because we have an incredible depth of primary, detailed data. Let's review the active threads and watches we can resolve or record. 1. **Active Watch: `Structure Therapeutics Q2 2026 Earnings Release`** - Fire date: 2026-08-06 - Summary: Structure reported on August 6, 2026. Dosed first patients in Phase 3 ACCOMPLISH program. Reported $106.2M net loss and $1.3B cash/short-term investments. - We should record this event and resolve the watch. 2. **Active Watch: `Amgen Q2 2026 Earnings Release`** - Fire date: 2026-08-04 - Summary: Amgen reported on August 4, 2026. Top revenues rose 10% to $10.1B, beat EPS at $6.29, discontinued early-stage obesity candidate AMG 513, and expanded the MariTide Phase 3 program (MARITIME program) with long-term maintenance and switching trials (MARITIME-SWITCH). - We should record this event and resolve the watch. 3. **Active Watch: `Structure Therapeutics Q3 2026 Phase 3 Aleniglipron Trial Initiation`** - Fire date: 2026-09-30 - Summary: Structure announced on August 6, 2026 that the first patients have been dosed in the Phase 3 ACCOMPLISH program. This has occurred ahead of schedule (or exactly in Q3 as planned)! - We should record this event and resolve the watch. Let's record the events first. Let's look at the parameters for `record_event`: - `thread_id`: we need to match the thread IDs from `list_threads`. - For `Structure Therapeutics Q2 2026 Earnings Release`, the ID is `019fc6ba-c7e2-7e34-8f48-01d4fadf0573`. - For `Amgen Q2 2026 Earnings Release`, the ID is `019fc6ba-7bbc-7435-8fc8-2d2cda459c06`. - For `Structure Therapeutics Q3 2026 Phase 3 Aleniglipron Trial Initiation`, the ID is `019eca60-7750-771f-9690-cf5d740535b4`. Let's call `record_event` on these three. Let's do it one by one. I'll state intent. First, I will record the event for Amgen's Q2 earnings release. This watch is resolved.

Now, I will record the event for Structure Therapeutics' Q2 earnings release. This watch is resolved.

Now, I will record the event for Structure Therapeutics' Phase 3 Aleniglipron Trial Initiation, which has officially occurred as of August 6, 2026, when the first patients were dosed in the ACCOMPLISH program. This watch is resolved.

I will also call `resolve_thread` for these three watches so they are marked as resolved in the system. First, resolve Amgen's Q2 earnings thread.

Next, resolve Structure's Q2 earnings thread.

Next, resolve Structure's Phase 3 Aleniglipron trial initiation thread.

Now, let's write our findings. We will write four distinct findings based on our research: 1. **Eli Lilly's Q2 2026 earnings & oral weight loss drug (Foundayo) vs. Novo Nordisk's Wegovy pill**: - Lilly reported $23B in Q2 revenue, raised guidance. - Foundayo (orforglipron) was approved on April 1, 2026, and generated $98M in Q2 (first quarter). Ex-US sales in UAE were $31M. - Novo Nordisk's Wegovy pill (approved Dec 2025) generated $496M in Q2 (up from $355M in Q1). - We will update the existing note on Cigna/employer cuts or GLP-1 competitive landscape, or write a fresh note. Let's see if there is an existing note we can update. - `glp1-competitive-landscape-ada-2026` tracks the competitive landscape. Let's update that note! 2. **Eli Lilly's legal dispute with the FDA over retatrutide's biologic status**: - Lilly plans to file for retatrutide in Q1 2027. - Legal war over whether it's a biologic (12-year exclusivity under BLA) or a drug (5-year exclusivity under NDA) because of the 40/41 amino acid count rule. - This is a brand new subject. Let's write a fresh note with a durable slug, e.g., `lilly-fda-retatrutide-biologic-dispute`. 3. **Amgen's Q2 2026 earnings, discontinuation of AMG 513, and MariTide's Phase 3 program (MARITIME)**: - Amgen beat expectations ($10.05B revenue, non-GAAP EPS of $6.29). - Discontinued early-stage candidate AMG 513, making MariTide their sole obesity asset. - Expanded MariTide Phase 3 program with long-term maintenance trials and MARITIME-SWITCH (switching patients from weekly tirzepatide/semaglutide to monthly/quarterly/bi-monthly MariTide). - This is a new subject or update. Wait, we don't have an Amgen-specific prior finding. Let's write a fresh note with a durable slug, e.g., `amgen-maritide-obesity-pipeline-q2-2026`. 4. **Structure Therapeutics' Q2 2026 earnings & ACCOMPLISH Phase 3 trial initiation**: - Dosed first patients in Phase 3 ACCOMPLISH. - Net loss of $106.2M, $1.3B cash/investments. - Upcoming data in Q4 2026 (Body Composition and SWITCH). - Let's update `structure-therapeutics-aleniglipron-access-ii-results` with these Q2 2026 details. Wait! Let's check the rules: - "Name a slug for the DURABLE SUBJECT it tracks: the throughline, entity, or running debate — never the transient story-of-the-day... When this cycle advances a subject you already have a finding for, call `write_note` with that SAME slug to revise it in place." - Let's double check the slugs of the prior findings. - `glp1-competitive-landscape-ada-2026` -> Wait, let's keep this as the main competitive landscape throughline! Let's update it. - `structure-therapeutics-aleniglipron-access-ii-results` -> This tracks Structure's aleniglipron results and pipeline. Let's update this note. - Let's create `lilly-fda-retatrutide-biologic-dispute` for the biologic classification fight. - Let's create `amgen-maritide-obesity-pipeline-q2-2026` -> Wait, let's name it `amgen-maritide-obesity-pipeline` as a durable slug! - Let's read the notes first if we want to check their existing content, but we don't have to if we can just write updated notes. Let's call `read_notes` first to make sure we don't miss anything. I'll state intent.

This is perfect. We have: 1. `glp1-competitive-landscape-ada-2026`: We can update this note to include the Q2 2026 commercial showdown between Lilly's Foundayo and Novo's Wegovy pill, plus Novo's 1.5 million worldwide patients and Lilly's $23B blowout. 2. `eli-lilly-foundayo-orforglipron-fda-approval`: This tracks Foundayo's FDA approval and commercial battle. Let's update this note instead or in addition, but wait! The guidelines say: "reusing a slug updates the existing note... Name a slug for the DURABLE SUBJECT it tracks... NEVER write a note that summarizes the cycle, bundles several unrelated subjects into one write-up... One finding = ONE coherent subject." So let's update: - `eli-lilly-foundayo-orforglipron-fda-approval` with the actual Q2 2026 sales figures ($98M for Foundayo vs $496M for the Wegovy pill) and commercial dynamics. - `lilly-retatrutide-phase-3-triumph-data` with the update that Lilly plans to file for approval in Q1 2027 and the legal/regulatory battle with the FDA over its biologic classification (BLA vs NDA). - `amgen-maritide-phase-2-results-maritime-phase-3` -> Wait, we have this existing note! This is perfect! Let's update this with their Q2 2026 earnings, discontinuation of AMG 513, and the MARITIME-SWITCH trial details. - `structure-therapeutics-aleniglipron-access-ii-results` -> Let's update this with their Q2 2026 earnings, dosing of first patients in the Phase 3 ACCOMPLISH program, and the $1.3B cash runway. Let's do this! This is a perfect mapping of 4 notes, all updating existing durable slugs. Let's write them one by one. ### First Note: `eli-lilly-foundayo-orforglipron-fda-approval` Let's review the contents we have: - Foundayo was approved on April 1, 2026. - In Q2 2026 (its first quarter on the market), Foundayo generated $98 million in sales (narrowly missing consensus). - Ex-US sales in UAE were $31 million, showing strong global potential. - Subscribers grew from 8,000 to 36,000, with volume doubling month-over-month. Nearly 1 in 4 patients choose Foundayo for initial starts. - Novo Nordisk's Wegovy pill (approved Dec 2025, launched Jan 2026) generated DKK 3.22B (~$496 million) in Q2 2026 (up from DKK 2.26B / $355M in Q1 2026). - Novo has 1.5 million patients on Wegovy pill worldwide, with over 5 million total prescriptions in the US. - Let's cite the market views and BioSpace/earnings call transcripts. Let's call `write_note` on `eli-lilly-foundayo-orforglipron-fda-approval`. I'll state intent.

This is fantastic. Now, let's write our second note: `lilly-retatrutide-phase-3-triumph-data`. Let's review what we have: - Lilly plans to submit retatrutide for global registrations in obesity, obstructive sleep apnea, and knee osteoarthritis pain in the **first quarter of 2027** (previously expected in late 2026). They are collecting some manufacturing-related data prior to submission. - There is a legal dispute between Lilly and the FDA over whether retatrutide is a biologic (Biologics License Application or BLA, giving 12 years of market exclusivity) or a drug (New Drug Application or NDA, giving 5 years). - Retatrutide has 41 amino acids. The FDA's rules define a protein as having 40 or more alpha amino acids. The FDA claims retatrutide does not have 40 or more *alpha* amino acids, and classified it as a drug. Lilly sued the FDA in September 2024, arguing that 41 is plainly greater than 40. - The courts vacated the FDA's biologic decision but returned the question of whether it is "analogous to a protein" to the FDA. Lilly has appealed and continues to pursue a BLA, hoping to resolve the issue before its Q1 2027 filing. Let's call `write_note` on `lilly-retatrutide-phase-3-triumph-data`. I'll state intent.

This is excellent. Now let's write our third note: `amgen-maritide-phase-2-results-maritime-phase-3`. Let's review what we have: - Amgen reported Q2 2026 earnings on August 4, 2026. - Total revenues rose 10% to $10.1 billion, and non-GAAP EPS was $6.29 (beating the $5.60 estimate). Free cash flow was $3.49 billion. - Amgen raised full-year guidance: revenue of $38.2B to $39.4B and non-GAAP EPS of $22.30 to $23.50. - **AMG 513 Discontinuation**: Amgen discontinued development of its Phase 1 oral obesity candidate AMG 513. It previously had been on clinical hold, and although the hold was lifted, Amgen decided to scrap it (following the culling of AMG 786 in May 2024), leaving **MariTide** as its sole weight loss asset. - **MariTide Phase 3 Expansion (MARITIME program)**: - MariTide is a monthly or quarterly antibody-peptide conjugate (activating GLP-1 and inhibiting GIP). - Ongoing Phase 3 trials: **MARITIME-1** (obesity, without T2D) and **MARITIME-2** (with T2D). - Newly initiated/enrolling trials: - **MARITIME-SWITCH**: Enrolling patients who switch from weekly tirzepatide (Lilly's Zepbound) or weekly semaglutide (Novo's Wegovy) to MariTide on an *every eight-week or quarterly dosing schedule*. This is a massive competitive differentiator! - **MARITIME-1 EXTENSION** and **MARITIME-2 EXTENSION**: 48-week extension trials evaluating long-term maintenance of weight loss with monthly, every eight-week, or quarterly dosing. - Three additional Phase 3 studies in Type 2 diabetes will be initiated in 2026. Let's call `write_note` on `amgen-maritide-phase-2-results-maritime-phase-3`. I'll state intent.

This is fantastic. Now let's write our fourth note: `structure-therapeutics-aleniglipron-access-ii-results`. Let's review what we have: - Structure Therapeutics reported Q2 2026 earnings on August 6, 2026. - Net Loss was $106.2 million for the quarter. - Cash, cash equivalents, and short-term investments totaled **$1.3 billion** as of June 30, 2026, which is expected to fund operations and clinical milestones through the end of 2028. - **Phase 3 ACCOMPLISH Program Initiation**: Announced that the first patients have been dosed in the Phase 3 ACCOMPLISH program (ACCOMPLISH-1 and ACCOMPLISH-2), which evaluates once-daily oral aleniglipron (GSBR-1290) for chronic weight management. This is a major milestone, putting them officially on track for their Q3 2026 timeline. - **Upcoming Data in H2 2026 (Q4 2026)**: - **Body Composition Study**: 44-week trial assessing aleniglipron's effect on body fat loss (topline expected in Q4 2026). - **SWITCH Study**: 12-week trial assessing transitioning patients from an approved injectable GLP-1 to once-daily oral aleniglipron for weight loss maintenance (topline expected in Q4 2026). - **Amylin Combination Trial**: Preclinical data showed aleniglipron + ACCG-2671 (oral amylin receptor agonist) demonstrated additional weight loss compared to monotherapy. A combination clinical trial is expected to initiate in Q4 2026. Let's call `write_note` on `structure-therapeutics-aleniglipron-access-ii-results`. I'll state intent.

All four notes have been written or updated successfully! Now, let's look at registering any forward-looking watches or threads. Let's see: 1. **Novo Nordisk's lower list price effective January 1, 2027**: - Novo Nordisk announced that effective January 1, 2027, it will lower the list price of Wegovy (semaglutide) injection 2.4 mg, 7.2 mg, and tablets up to 25 mg, and Ozempic injection 0.5 mg, 1 mg, 2 mg, and tablets 7 mg or 14 mg to **$675**. This is a massive tripwire/milestone! Let's register a watch for this. 2. **Eli Lilly's retatrutide regulatory submission in Q1 2027**: - Eli Lilly plans to submit retatrutide for approval in Q1 2027. This is a dated catalyst. Let's register a watch for this. 3. **Structure Therapeutics' upcoming Q4 2026 data readouts**: - Body Composition clinical trial (44-week) and SWITCH clinical trial (12-week maintenance) data are expected in Q4 2026. This is a dated catalyst. Let's register a watch for this. 4. **Amgen's MariTide Type 2 diabetes Phase 3 trial initiations in 2026**: - Three Phase 3 studies in Type 2 diabetes will be initiated in 2026. This is a dated catalyst. Let's register a watch. Let's register these watches! I will use `record_watch` to register them. I'll state intent. First, register a watch for Novo Nordisk's list price reductions effective January 1, 2027. This is a dated catalyst / tripwire. Let's use `dated_catalyst` or `tripwire`. Let's use `dated_catalyst`. Since it's effective Jan 1, 2027, let's set `fire_date` to `2027-01-01T00:00:00Z`. Let's do it.

Ah! I forgot `watch_type`. Let me check the enum values for `watch_type`: `enum: ["dated_catalyst", "scheduled_release", "metric_threshold", "live_process", "tripwire", "thesis_breaker"]` Let's use `dated_catalyst` for the list price cut. Let's do it.

Awesome. Now, let's register a watch for Eli Lilly's retatrutide regulatory submission in Q1 2027. This is a dated catalyst. Let's set `fire_date` to `2027-03-31T23:59:59Z`. Let's do it.

Excellent. Now, let's register a watch for Structure Therapeutics' upcoming Q4 2026 aleniglipron data readouts (Body Composition and SWITCH). Let's set `fire_date` to `2026-12-31T23:59:59Z`. Let's do it.

Great. Now, let's register a watch for Amgen's initiation of three Phase 3 studies of MariTide in Type 2 diabetes in 2026. Let's set `fire_date` to `2026-12-31T23:59:59Z`. Let's do it.

Perfect. All watches are recorded. Let's make sure we have recorded all threads and resolved everything. Let's call `finish_cycle` to complete this research cycle. I'll state intent.

I have completed the research cycle. Here is a summary of the key findings and updates: ### 1. Oral GLP-1 Showdown: Eli Lilly's Foundayo vs. Novo Nordisk's Wegovy Pill The competitive battle in the once-daily oral GLP-1 receptor agonist market intensified significantly in Q2 2026. * **Eli Lilly (NYSE: LLY)** recorded its first quarter of commercial availability for its oral obesity pill, **Foundayo™ (orforglipron)**, generating **$98 million** in sales (narrowly missing consensus). While the U.S. launch was slow, ex-U.S. performance was strong, with **$31 million** in sales coming solely from the UAE. Lilly USA's subscriber base grew from 8,000 to **36,000 subscribers** during the quarter. * **Novo Nordisk (NYSE: NVO)** demonstrated immense commercial momentum with its **Wegovy® pill** (approved in Dec 2025), which generated **$496 million** (DKK 3.22 billion) in adjusted Q2 2026 sales (up from $355 million in Q1). It has captured roughly **90% of the oral obesity medication market** in the U.S., surpassing **5 million total prescriptions** since its launch. * **List Price Cuts:** In a major move to unlock volume, Novo Nordisk announced that, effective **January 1, 2027**, it will lower the U.S. list price of its primary semaglutide products (including the Wegovy pill and Wegovy/Ozempic injectables) to **$675**, representing a ~50% reduction for Wegovy. * *Finding updated under slug:* `eli-lilly-foundayo-orforglipron-fda-approval` ### 2. Eli Lilly Delays Retatrutide Submission to Q1 2027 Amid FDA Biologic Classification Dispute * **Submission Delayed:** Lilly has rescheduled the regulatory submission of **retatrutide** (its triple GLP-1/GIP/glucagon agonist) for **Q1 2027** (previously expected in late 2026) to collect additional manufacturing data. * **BLA vs. NDA Legal Battle:** Lilly and the FDA are engaged in a high-stakes legal battle over whether retatrutide is a biologic (which would grant **12 years of market exclusivity** under a BLA) or a drug (which would grant only **5 years** under an NDA). Retatrutide has 41 amino acids; Lilly argues that since "41 is plainly greater than 40," it meets the FDA's definition of a protein. The FDA rejects this, arguing it does not contain 40 or more *alpha* amino acids. * *Finding updated under slug:* `lilly-retatrutide-phase-3-triumph-data` ### 3. Amgen Consolidates Focus on MariTide, Discontinues AMG 513 * **Q2 2026 Blowout:** Amgen (NASDAQ: AMGN) reported Q2 2026 revenues of **$10.05 billion** (+10% YoY) and a non-GAAP EPS of **$6.29** (beating the $5.60 estimate), prompting it to raise full-year guidance. * **Pipeline Rationalization:** Amgen announced it is **discontinuing AMG 513** (its Phase 1 oral obesity candidate), leaving **MariTide** as its sole weight-loss asset. * **MARITIME-SWITCH Strategy:** Amgen is aggressively enrolling patients in **MARITIME-SWITCH**, a Phase 3 trial evaluating the transition of patients from weekly tirzepatide or semaglutide to MariTide on an **every eight-week or quarterly dosing schedule**. * *Finding updated under slug:* `amgen-maritide-phase-2-results-maritime-phase-3` ### 4. Structure Therapeutics Initiates Phase 3 ACCOMPLISH Program * **ACCOMPLISH Dosing:** On August 6, 2026, Structure Therapeutics (NASDAQ: GPCR) announced that the **first patients have been dosed** in its Phase 3 ACCOMPLISH program (ACCOMPLISH-1 and ACCOMPLISH-2) evaluating oral **aleniglipron (GSBR-1290)** for chronic weight management. * **Liquidity & Runway:** Structure reported a Q2 2026 net loss of **$106.2 million** but holds **$1.3 billion** in cash, cash equivalents, and short-term investments, securing its runway **through the end of 2028**. * **Catalysts:** Topline data from aleniglipron's 44-week Body Composition trial and 12-week SWITCH trial are expected in **Q4 2026**. * *Finding updated under slug:* `structure-therapeutics-aleniglipron-access-ii-results` ### 5. Resolved Threads & New Watches Registered * **Resolved Threads:** * `Structure Therapeutics Q2 2026 Earnings Release` (Resolved) * `Amgen Q2 2026 Earnings Release` (Resolved) * `Structure Therapeutics Q3 2026 Phase 3 Aleniglipron Trial Initiation` (Resolved) * **New Watches Registered:** * `Novo Nordisk Wegovy and Ozempic $675 List Price Cut Implementation` (Dated Catalyst, January 1, 2027) * `Eli Lilly Retatrutide Regulatory Submission in Obesity and Comorbidities` (Dated Catalyst, Q1 2027) * `Structure Therapeutics Aleniglipron Body Composition and SWITCH Trial Readouts` (Dated Catalyst, Q4 2026) * `Amgen MariTide Type 2 Diabetes Phase 3 Trial Initiations` (Dated Catalyst, late 2026)